Dr. Majed Chane is a principal investigator on the following pivotal clinical issues in national and international clinical research trials:
- Evaluate cardiovascular outcomes in diabetic patients after treatment with novel medication
- Evaluate effects of novel medication on patients with heart disease and Hyper-Cholesterolemia
- National Outcomes registry for Atrial Fibrillation patients
- Analyze the efficacy and safety of novel medication in patients with high cholesterol
- Assess cardiovascular event in patient started on novel medication for weight management
- Evaluate the incidence of cardiovascular events in patients when taking a novel cholesterol lowering medication
- Measure the affordability of antiplatelet therapy on patients after experiencing a heart attack
- Evaluate the effect of antiplatelet therapy on heath outcomes in patients with Diabetes Mellitus
- Analyze the effects of blood thinning medications in combination on patients with atrial fibrillation and coronary artery disease
- Monitor the safety and efficacy of taking study medication with or without food in patients who have high potassium
- Analyze the effect of anti coagulation therapy in combination on patient with atrial fibrillation
- Observational registry of treatment patterns in U.S patients with heart failure
- Evaluate cardiovascular risk in a genetically defined population with coronary syndrome while taking the study drug
Clinical Research Expertise
- Coronary Artery Disease and Atrial Fibrillation / Flutter
- Heart Failure Management
- Atrial Fibrilation
- Obesity and Cardiovascular Risk Factors
- Anti-inflammation treatment and Coronary Artery Disease
- Antiplatelet Treatment and Coronary Artery Disease
- High Cholesterol
- High Potassium / Hyperkalemia
- Coronary Artery Disease and specific gene testing
- Type 2 Diabetes
Sponsors
As an additional testament to Dr. Chane commitment to delivering state of the art cardiovascular care, has been selected to serve as a lead principal investigator with the following national and an international sponsors:
